SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.15+2.5%Jan 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Biomaven10/28/2014 10:14:36 AM
   of 52153
 
Had a chance to speak with my nephew who's an oncology fellow at Hopkins specializing in prostate cancer.

From an actionable perspective, he said he's now a supporter of PSA testing as more data has come in and as watchful waiting has become more common.

From a drug development perspective, he sees the androgen receptor drugs as being near the end of their development line, with perhaps only the Aragon drug being a potential improvement. Xtandi's biggest problem is fatigue. So people are looking for the next line of attack.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News